Clinical characteristics and airway inflammation profile of COPD persistent sputum producers

Respiratory Medicine

Volumn 108, Issue 12, 2014, Pages 1761-1770

  Khurana, S ^a   Ravi, A ^a   Sutula, J ^a   Milone, R ^b   Williamson, R ^b   Plumb, J ^a   Vestbo, J ^a   Singh, D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chronic bronchitis; COPD; Persistent sputum producer

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DITHIOTHREITOL; EOTAXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

AGED; ARTICLE; BACTERIAL COLONIZATION; CELL VIABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE ASSESSMENT TOOL; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE EXACERBATION; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LEUKOCYTE COUNT; LIMIT OF DETECTION; LUNG CLOSING VOLUME; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; REPRODUCIBILITY; RESIDUAL VOLUME; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS; SPUTUM CULTURE; SQUAMOUS CELL; ST. GEORGE RESPIRATORY QUESTIONNAIRE; THIN LAYER CHROMATOGRAPHY; TOTAL LUNG CAPACITY; BACTERIUM; BIOSYNTHESIS; BRONCHITIS, CHRONIC; CELL COUNT; COMPLICATION; CYTOLOGY; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SECRETION (PROCESS); SEVERITY OF ILLNESS INDEX; SPUTUM;

AGED; BACTERIA; BRONCHITIS, CHRONIC; CELL COUNT; CYTOKINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPECIMEN HANDLING; SPUTUM;

EID: 84927656001     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.09.020     Document Type: Article

References (52)

1. Hogg JC, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(26): 2645-53.
2. Han MK, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182(5): 598-604.
3. de Oca MM, et al. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J 2012; 40(1): 28-36.
4. Corhay JL, et al. Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study. Int J Clin Pract 2013; 67(12): 1294-301.
5. 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5): 1530-5.
6. Burgel PR, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135(4): 975-82.
7. Miravitlles M, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67(5): 495-501.
8. Seemungal TA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(5 Pt 1): 1418-22.
9. Ekberg-Aronsson M, et al. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005; 6: 98.
10. Lange P, et al. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45(8): 579-85.
11. Pelkonen M, et al. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130(4): 1129-37.
12. Kim V, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011; 140(3): 626-33.
13. Agusti A, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
14. Rose MC, Lynn WS, Kaufman B. Resolution of the major components of human lung mucosal gel and their capabilities for reaggregation and gel formation. Biochemistry 1979; 18(18): 4030-7.
15. Caramori G, et al. MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology 2009; 55(3): 321-31.
16. Innes AL, et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006; 130(4): 1102-8.
17. Thai P, et al. Regulation of airway mucin gene expression. Annu Rev Physiol 2008; 70: 405-29.
18. Balbi B, et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997; 10(4): 846-50.
19. Capelli A, et al. Increased MCP-1 and MIP-1 beta in bron-choalveolar lavage fluid of chronic bronchitics. Eur Respir J 1999; 14(1): 160-5.
20. Chanez P, et al. Interleukin 8 in bronchoalveolar lavage of asthmatic and chronic bronchitis patients. Int Arch Allergy Immunol 1996; 111(1): 83-8.
21. Snoeck-Stroband JB, et al. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 2008; 31(1): 70-7.
22. Miotto D, et al. Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis. Eur Respir J 2003; 22(4): 602-8.
23. Bafadhel M, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 2012; 83(1): 36-44.
24. GOLD. Global strategy for the diagnosis, prevention and management of chronic obstructive pulmonary disease. 2011.
25. ATS-DLD-78-A. Recommended respiratory disease questionnaires for use with adults and children in epidemiological research. 1969 [cited; Available from: http://www-archive.thoracic.org/sections/publications/statements/pages/archive/rrdquacer.html.
26. Celli BR, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10): 1005-12.
27. Pizzichini E, et al. Safety of sputum induction. Eur Respir J Suppl 2002; 37: 9s-18s.
28. Barrow GI, F.R. Cowan and steel's manual for the identification of medical bacteria. 1993.
29. Singh D, et al. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 2010; 11: 77.
30. Bottai M, et al. Longitudinal changes of body mass index, spirometry and diffusion in a general population. Eur Respir J 2002; 20(3): 665-73.
31. Enache, I., et al. Impact of altered alveolar volume on the diffusing capacity of the lung for carbon monoxide in obesity. Respiration; 81(3): 217-222.
32. Chen Y, et al. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 2003; 278(19): 17036-43.
33. Monzon ME, Forteza RM, Casalino-Matsuda SM. MCP-1/CCR2B-dependent loop upregulates MUC5AC and MUC5B in human airway epithelium. Am J Physiol Lung Cell Mol Physiol 2011; 300(2):L204-15.
34. Song KS, et al. Interleukin-1 beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J Biol Chem 2003; 278(26): 23243-50.
35. Garcia-Zepeda EA, et al. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC che-mokine receptors (CCR)-2 and -3. J Immunol 1996; 157(12): 5613-26.
36. Ferrante A. Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors. Immunol Ser 1992; 57: 417-36.
37. Zhu Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103(6): 779-88.
38. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1(1): 39-47.
39. Pizzichini E, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158(5): 1511-7.
40. Bocchino V, et al. Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy 2002; 57(1): 17-22.
41. Burgel PR, et al. Human eosinophils induce mucin production in airway epithelial cells via epidermal growth factor receptor activation. J Immunol 2001; 167(10): 5948-54.
42. Shimizu T, et al. A mechanism of antigen-induced goblet cell degranulation in the nasal epithelium of sensitized rats. J Allergy Clin Immunol 2003; 112(1): 119-25.
43. Bhowmik A, et al. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax 1998; 53(11): 953-6.
44. Moretti M. Spontaneous and induced sputum to measure indices of airway inflammation in COPD. Eur J Respir Dis Suppl 1999; 14(Suppl. 30): 24s.
45. Sapey E, et al. Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intrapatient and inter-patient variability. Thorax 2008; 63(6): 493-9.
46. Hurst JR, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363(12): 1128-38.
47. O'Brien C, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55(8): 635-42.
48. Patel IS, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170(4): 400-7.
49. Martinez-Garcia MA, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187(8): 823-31.
50. Iwamoto H, et al. Differences in plasma and sputum bio-markers between COPD and COPD-asthma overlap. Eur Respir J 2013; 43(2): 421-9.
51. Ropcke S, et al. Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PLoS One 2012; 7(10):e46207.
52. Singh D, et al. Induced sputum genes associated with spiro-metric and radiological disease severity in COPD ex-smokers. Thorax 2011; 66: 489-95.